Fundraising Fox
Pamela Klein
InvestorFounder and Principal, PMK BioResearch at Ysios Capital
San Francisco, California, United States
Find your path to Pamela
Sign up to see every warm intro you have to Pamela
- Paths you didn't know you had: your email and LinkedIn already hold routes to Pamela. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
About
Dr. Pamela M. Klein is founder and principal of PMK BioResearch, providing advisory and strategic consulting to the biotechnology industry, and serves as consulting Chief Medical Officer of Olema Oncology. She previously held Chief Medical Officer roles at several biotech companies, including Intellikine (acquired by Takeda), and worked at Genentech from 2001 to 2008, ending as Vice President of Development where she oversaw development of drugs such as trastuzumab, rituximab, pertuzumab and erlotinib. She earlier co-founded and served as research director for the National Cancer Institute–Navy Breast Care Center, holds a biology degree from California State University Northridge and a medical degree from Loyola University Chicago's Stritch School of Medicine, and trained in internal medicine and medical oncology.
Invests in
Biotech
Investments
Board seats
ArgenxF-Star TherapeuticsI-Mab BiopharmaJiya Acquisition CorporationPatrys
Per the firm's website.
Colleagues at Ysios Capital
Frequently asked questions
- Who is Pamela Klein?
- Dr. Pamela M. Klein is founder and principal of PMK BioResearch, providing advisory and strategic consulting to the biotechnology industry, and serves as consulting Chief Medical Officer of Olema Oncology. She previously held Chief Medical Officer roles at several biotech companies, including Intellikine (acquired by Takeda), and worked at Genentech from 2001 to 2008, ending as Vice President of Development where she oversaw development of drugs such as trastuzumab, rituximab, pertuzumab and erlotinib. She earlier co-founded and served as research director for the National Cancer Institute–Navy Breast Care Center, holds a biology degree from California State University Northridge and a medical degree from Loyola University Chicago's Stritch School of Medicine, and trained in internal medicine and medical oncology.
- Where does Pamela Klein work?
- Pamela Klein is Founder and Principal, PMK BioResearch at Ysios Capital.
- What does Pamela Klein invest in?
- Pamela Klein invests in Biotech.
- What boards does Pamela Klein sit on?
- Pamela Klein holds tracked board seats at Argenx, F-Star Therapeutics, I-Mab Biopharma, Jiya Acquisition Corporation, Patrys.
About this profile. Compiled from public sources — Ysios Capital's own website and public professional profiles — and summarised by Fundraising Fox; every fact is kept with where it came from. Spotted an error, or would rather not be listed? Email privacy@fundraisingfox.com · How we build profiles · Your rights